Optimer Pharmaceutic (NASDAQ: OPTR) was downgraded by research analysts at JMP Securities to a “market perform” rating in a report released on Friday.
Shares of Optimer Pharmaceutic opened at 12.12 on Friday. Optimer Pharmaceutic has a one year low of $8.64 and a one year high of $16.49. The stock’s 50-day moving average is currently $10.52. The company’s market cap is $578.0 million.
Optimer Pharmaceutic last announced its earnings results on Thursday, February 28th. The company reported $0.02 earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.57) by $0.59. The company had revenue of $19.50 million for the quarter, compared to the consensus estimate of $18.05 million. During the same quarter last year, the company posted $0.29 earnings per share. Optimer Pharmaceutic’s revenue was down 69.8% compared to the same quarter last year. On average, analysts predict that Optimer Pharmaceutic will post $-1.19 earnings per share for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at Robert W. Baird reiterated an “outperform” rating on shares of Optimer Pharmaceutic in a research note to investors on Thursday. They now have a $16.00 price target on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Optimer Pharmaceutic in a research note to investors on Friday, January 11th. They now have a $11.00 price target on the stock.
Six equities research analysts have rated the stock with a buy rating, one has given an overweight rating, one has issued a hold rating, and one has assigned an underweight rating to the company’s stock. Optimer Pharmaceutic has an average rating of “overweight” and a consensus target price of $18.12.
Optimer Pharmaceuticals, Inc. (Optimer) is a biopharmaceutical company focused on developing and commercializing hospital specialty products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
